Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.
A surprising form of cell-to-cell communication in glioblastoma promotes global changes in recipient cells, including aggressiveness, motility, and resistance to radiation or chemotherapy.
Researchers have uncovered a trigger for an immune-related cell death pathway called necroptosis. The discovery could be used to develop new treatments for cancer and immune disorders.
Oxidative stress can help tumors thrive, but one way novel cancer treatments work is by pushing levels to the point where it instead helps them die, scientists report.
Researchers from Osaka University have discovered how precancerous cells spread to normal tissue and cause cancer.
The ERMA cohort comprises women aged 47 to 55 years living in the city of Jyväskylä and surrounding municipalities in Finland. The original invitation was posted to 82% of the cohort and 47% answered the invitation.
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved Venclexta in combination with Rituxan for the treatment of people with chronic lymphocytic leukemia or small lymphocytic lymphoma, with or without 17p deletion, who have received at least one prior therapy.
Scientists at Virginia Commonwealth University believe they have uncovered an "Achilles heel" of glioblastoma multiforme, the most common and deadly form of brain cancer.
Thanks to advances in the development of anti-retroviral therapy (ART), patients with HIV are living longer than ever before. And yet, even in patients on very effective, long-term ART, HIV persists, requiring patients to take antiviral medication life-long.
How can we detect cancer and viruses with high sensitivity? Physical chemist Laura Fabris-;an associate professor in the Materials Science and Engineering Department at Rutgers, the State University of New Jersey, and principal investigator of the Fabris NanoBio Group-;is addressing this very question.
Researchers from Case Western Reserve University School of Medicine have discovered how unusually long strands of RNA help colon cancer cells avoid death, allowing unregulated growth.
Recent studies in the journal Molecular & Cellular Proteomics have shed light on pathogenic mechanisms of the sexually-transmitted parasite Trichomonas vaginalis and the HIV-associated opportunistic lung fungus Aspergillus.
TRAIL, a member of the TNF family of ligands, causes caspase-dependent apoptosis through activation of its receptors, death receptor 4 and DR5.
Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia don't respond to chimeric antigen receptor T cell therapy, and the answer is tied to how primed patients' immune systems are before the therapy is administered.
Research into cancer can provide new insight into how this disease works and how it can be stopped. The Experimental Biology 2018 meeting will showcase innovative research that could lead to new ways to treat and prevent cancer.
An experimental compound appears to improve stroke outcome by reducing the destructive inflammation that can continue months after a stroke, scientists report.
A UNLV scientist and her team have found that frog embryos can fully regrow their eyes after injuries, a breakthrough that may lead one day to the ability to orchestrate tissue regeneration in humans.
Existing microscopy-based methods of detecting apoptosis, such as TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling), have limited quantitative capabilities due to insufficient signal-to-noise ratios.
Many chemotherapeutics act by damaging the DNA. Since cancer cells divide more often than most normal cells, they react more sensitive to DNA damaging agents.
Amyotrophic lateral sclerosis is a neurodegenerative disease damaging motor neurons in brain and spinal cords. ALS patients show progressive muscle weakness and atrophy, leading to a fatal respiratory muscle paralysis. There are no effective therapies for ALS.
SYGNIS AG, the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced the launch of its TruePrime apoptotic cell free DNA amplification kit, under the Expedeon brand.